INS and metabolic dysfunction-associated steatotic liver disease: A recent study demonstrated that obese people with normal IHTG content are “protected” from the development of adverse metabolic changes after moderate weight gain (~6% of initial body weight); conversely, BMI- and body fat mass-matched obese subjects with high IHTG content (i.e., NAFLD) are prone to further deterioration of insulin action in the liver, adipose tissue, and skeletal muscle in response to moderate weight gain [34] (Figure 1).